I was wondering what some people here thought about the hire of Liza Squires as US Chief Medical Officer for Neuren. Given this is a new position within the company, I find this development intriguing because if its Neuren's intention to farm out the 4 NNZ-2591 indications would you not leave this to prospective suitors to deal with the program and everything it entails (bureaucracy, design, leasing with stakeholders etc)? Did they have someone in a similar position based in Australia (James Shaw?) and this person was the link between the FDA, Acadia and Neuren?
Liza Squires I believe has had success in bringing new drugs to market. This is her expertise, knowing that and with the new position being created I'm inclined to think Neuren is going to have a go at bringing NNZ-2591 to market by themselves.
Share Price, page-3151
-
- There are more pages in this discussion • 7,805 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.17 |
Change
0.070(0.35%) |
Mkt cap ! $2.578B | |||
| Open | High | Low | Value | Volume |
| $20.39 | $20.53 | $20.14 | $4.102M | 202.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 249 | $20.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.31 | 790 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |